Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, ~1,200 stem cell transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing world-class cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
SERDs, ADCs Broaden Research Avenues Throughout Breast Cancer
October 8th 2021Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.
Darovasertib Shows Encouraging Activity in Metastatic Uveal Melanoma
Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.
Experts Provide Real-World Advice for Molecular Testing in Gastrointestinal Malignancies
January 25th 2021Johanna C. Bendell, MD, moderates a peer exchange with fellow experts to discuss differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma, and treatment options for patients with BRAF-mutant, microsatellite instability–high colorectal cancer.
Johnson Assumes Director Post of Lung Cancer Research at Sarah Cannon Research Institute
Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.
Lung Cancer: Co-Chaired by David Spigel, MD and Melissa L. Johnson, MD
December 3rd 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of lung cancer.
Gastrointestinal Malignancies: Chaired by Johanna Bendell, MD
November 17th 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of gastrointestinal cancers.